Abstract 388P
Background
Bevacizumab (Avastin®) is a monoclonal antibody targeting the vascular endothelial growth factor (VEGF). Used alone or in combination with chemotherapy and/or immunotherapy, there is confirmed efficacy in many cancers.
Methods
In this randomized, double-blind, multicenter, phase III, treatment naive, locally advanced, metastatic, or recurrent EGFR wildtype non-squamous, non small cell lung cancer (nsNSCLC) patients were enrolled and randomized (1:1) into TAB008 or Avastin® groups. Patients received 4-6 (3 week)cycles of paclitaxel/carboplatin plus TAB008 or Avastin® at 15mg/kg intravenously, followed by 7.5mg/kg maintenance dose until disease progression, unacceptable toxicity, or death. The primary endpoint compared the objective response rate (ORR) within 6 cycles as read by an independent radiological review committee (IRRC). Secondary endpoints included disease control rate (DCR), duration of response (DoR), progression free survival (PFS), 1 year overall survival rate (OSR), overall survival (OS), safety, immunogenicity, and pharmacological bio-equivalence of Cmin under steady state conditions.
Results
A total of 549 nsNSCLC patients were enrolled (277 in the TAB008 group, 272 in the Avastin® group). In the full analysis set, ORRs were 55.957% for TAB008, and 55.720% for Avastin®, the 90% CI was 0.89-1.14, well within the predefined equivalence margin of 0.75-1.33. No significant differences were found in DCR within 6 cycles (95.7% vs 95.4%, p=0.8536), DoR (8.17 vs 7.3 months, p=0.3526), PFS (9.10 vs 7.97 months, p=0.9457), 1 year OSR (66.2 vs 68%, p=0.6793), or OS (20.4 vs 17.4 months, p=0.6594). Serious adverse events (AEs) occurred in 37.55% (104/277) and 34.32% (93/271) in the TAB008 and Avastin® groups. Anti-drug antibodies were reported in 3/277 (1.08%) and 5/271(1.85%) in the TAB008 and Avastin® groups. Steady-state trough concentrations (Cmin) were 106.13 and 96.03μg/mL in the TAB008 and Avastin® groups, with the treatment group ratio of LS geometric means is contained within the bioequivalence limits of 80.00–125.00% (90% CI: 101.74%-120.05%).
Conclusions
TAB008 is similar to bevacizumab(Avastin®) in terms of efficacy, safety, and pharmacokinetic parameters.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
TOT BIOPHARM.
Funding
TOT BIOPHARM.
Disclosure
X. Li, L. Wang: Full/Part-time employment: TOT BIOPHARM. All other authors have declared no conflicts of interest.
Resources from the same session
371P - Real-world insights into treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): KINDLE study India analysis
Presenter: Kumar Prabhash
Session: e-Poster Display Session
372P - Treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Real-world experience in Singapore from the KINDLE study
Presenter: Ross A. Soo
Session: e-Poster Display Session
373P - Chromatin accessibility reveals potential prognostic value of the peak set associated with smoking history in patients with lung adenocarcinoma
Presenter: Jianlian Deng
Session: e-Poster Display Session
384P - BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
Presenter: Stefanie Schalm
Session: e-Poster Display Session
385P - Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
Presenter: Fabrice Barlesi
Session: e-Poster Display Session
386P - A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: LI Zhou
Session: e-Poster Display Session
387P - Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C
Presenter: Tomonori Hirashima
Session: e-Poster Display Session
389P - Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%
Presenter: Yi-Long Wu
Session: e-Poster Display Session
391P - Economic impact of next-generation sequencing (NGS) versus single-gene testing modalities to detect genomic alterations (GAs) in metastatic non-small cell lung cancer (mNSCLC) in Asia
Presenter: Herbert Loong
Session: e-Poster Display Session
392P - Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-positive non-small cell lung cancer patients with brain metastases in China
Presenter: Zhixin Qiu
Session: e-Poster Display Session